About Halcyon Biomedical
Halcyon Biomedical is a Healthcare company based in Friendswood (United States) founded in 2013. Diagnostic solutions for hematological disorders. Halcyon Biomedical offers products and services including Lymphocyte Isolation, Large Cell Enrichment, and WBC Isolation. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Hemoglobinopathies. Its legal entity is Halcyon Biomedical Incorporated. Its competitors include Hemex Health, BioMedomics and Silver Lake Research Corporation; 2 of its 3 listed competitors have raised funding.
Company details
Halcyon Biomedical develops diagnostic solutions for hematological disorders. Its flagship product utilizes differences in blood spread between normal blood and blood from a patient with sickle cell anemia, as seen on a chromatography paper, to diagnose the disease. In addition, the company is also developing a portable whole blood separator, a microfluidic device that enables separation of leukocytes from platelet-rich plasma, a lab-on-chip device for the selective enrichment of cell types in whole blood, a cell sorter focused on circulating tumor cells, and a platform for the enrichment of exosomes.
- Headquarters Friendswood, United States
- SectorsHealthcare
- Website halcyonbiomedical.com
- Legal Name Halcyon Biomedical Incorporated
- Latest Funding Round$749.4K (USD), Grant
May 2020
- InvestorsHHS
& 1 more
Products & Services of Halcyon Biomedical
Halcyon Biomedical offers a comprehensive portfolio of products and services, including Lymphocyte Isolation, Large Cell Enrichment, and WBC Isolation.
Service for isolating lymphocytes from whole blood samples
Process for enriching monocytes and CTC from undiluted blood
Method for isolating white blood cells from leukopaks
Funding Insights of Halcyon Biomedical
- Total Rounds 3
- Last Round Grant — $749,400
- First Round $1.45M
(Aug 2014)
- Investors Count 2
All 3 funding rounds of Halcyon Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $749,400 | Grant | – | – | |
| Feb 2019 | $225,000 | Grant | – | – | |
| Aug 2014 | $1.45M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Halcyon Biomedical
Halcyon Biomedical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and America’s Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Halcyon Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Halcyon Biomedical
3 dated milestones of Halcyon Biomedical across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Halcyon Biomedical is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Grant, of $749K.
Competitors of Halcyon Biomedical
Halcyon Biomedical has 3 listed competitors in our database, 2 of them funded. They include Hemex Health, BioMedomics and Silver Lake Research Corporation.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hemexhealth.com | 2016 | Portland, United States | $6.24M | 33 | Platform providing care devices for the detection of tropical diseases | |
| biomedomics.com | 2006 | Durham, United States | $1.5M | 14 | Point-of-care diagnostic systems for blood-based disorders are developed. | |
| silverlakeresearch.com | 1993 | United States | 32 | Custom antibodies and diagnostics are developed for various applications. |
Detailed competitors of Halcyon Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as Halcyon Biomedical (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Halcyon Biomedical
Halcyon Biomedical was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Halcyon Biomedical is headquartered in Friendswood, United States. It is registered at Friendswood, Texas, United States.
Halcyon Biomedical develops diagnostic solutions for hematological disorders. Its flagship product utilizes differences in blood spread between normal blood and blood from a patient with sickle cell anemia, as seen on a chromatography paper, to diagnose the disease. In addition, the company is also developing a portable whole blood separator, a microfluidic device that enables separation of leukocytes from platelet-rich plasma, a lab-on-chip device for the selective enrichment of cell types in whole blood, a cell sorter focused on circulating tumor cells, and a platform for the enrichment of exosomes.
Halcyon Biomedical's top competitors include Hemex Health, Silver Lake Research Corporation and BioMedomics.
Halcyon Biomedical offers Lymphocyte Isolation, Large Cell Enrichment, and WBC Isolation.
Halcyon Biomedical has 2 investors. Key investors include HHS, and America’s Seed Fund.
Halcyon Biomedical operates through Halcyon Biomedical Incorporated.